Quantum Computing Inc Sees Surge in Options Trading Volume
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: NASDAQ.COM
- Surge in Options Volume: Quantum Computing Inc (QUBT) experienced an options trading volume of 199,735 contracts today, equating to approximately 20 million shares, which represents about 80.3% of its average daily trading volume of 24.9 million shares over the past month, indicating strong market interest in its future performance.
- High-Frequency Trading Insights: Notably, the $13 strike call option expiring on May 22, 2026, saw a trading volume of 29,538 contracts today, representing around 3 million underlying shares, suggesting a significant bullish sentiment among investors regarding QUBT's stock price appreciation.
- Qorvo Options Activity: Concurrently, Qorvo Inc (QRVO) recorded an options trading volume of 9,316 contracts today, equivalent to approximately 931,600 shares, which accounts for 77.1% of its average daily trading volume of 1.2 million shares over the past month, reflecting sustained investor interest in its stock.
- Strike Price Focus: For QRVO, the $120 strike call option expiring on December 18, 2026, has seen a trading volume of 2,611 contracts today, representing about 261,100 underlying shares, indicating optimistic market expectations for its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 234.200
Low
190.00
Averages
218.50
High
240.00
Current: 234.200
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Alternatives Amid Tech Stock Surge
- Market Volatility Risk: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating a heavy reliance on tech, prompting investors to consider diversification to mitigate risks.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, demonstrates sustained innovation through its research-driven operations in pharmaceuticals and medical devices, ensuring it remains competitive in a fierce market.
- Stable Dividend Returns: With over 50 consecutive years of dividend increases, Johnson & Johnson has earned the title of 'Dividend King', reflecting its strong execution and business resilience, appealing to investors seeking stable returns.
- Healthcare Sector Resilience: Demand for medical services remains steady during economic downturns, and Johnson & Johnson's business exhibits higher stability amid economic fluctuations, making it a solid alternative to tech stocks.
See More
2026 Consumer Goods Market Analysis
- Church & Dwight's Strong Performance: Church & Dwight (CHD) achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, indicating the company's ability to navigate inflation through volume growth rather than price increases, thereby enhancing its market competitiveness.
- Keurig Dr Pepper's Growth Potential: Despite a nearly 29% decline from its 2025 peak, Keurig Dr Pepper (KDP) expects its energy drink portfolio to generate over $1 billion in annual retail sales, showcasing strong market demand and growth potential.
- Kenvue's Merger Prospects: Kenvue (KVUE) reported an 8.4% growth in its skin health and beauty division in Q1 2026, with quarterly sales reaching $1 billion, and the anticipated merger with Kimberly-Clark (KMB) is expected to further strengthen its market position and pricing power.
- Robust Investment Amid Market Uncertainty: In an uncertain market, these three companies provide a stable business foundation, making them suitable for investors looking to allocate $1,000 during turbulent times for long-term growth.
See More
Church & Dwight's Growth Strategy Amid Inflation
- Stable Sales Growth: Church & Dwight achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, demonstrating its growth strategy focused on volume rather than price increases, which enhances its competitive edge in an inflationary environment.
- Acquisition to Expand Market Share: The company acquired the fast-growing stain-removal brand Miss Mouth's Messy Eater for $325 million, continuing its decade-long acquisition strategy aimed at expanding market share without increasing leverage, thereby solidifying its position in the consumer goods market.
- Energy Drink Portfolio Growth: Keurig Dr Pepper's energy drink portfolio is expected to exceed $1 billion in annual retail sales, and despite a 29% decline in stock price, its low double-digit adjusted earnings growth forecast indicates potential in the youth market, boosting investor confidence.
- Strong Performance in Beauty Health Segment: Kenvue's skin health and beauty division grew 8.4% in Q1 2026, reaching $1 billion in quarterly sales, reflecting stable consumer demand amid economic uncertainty, with the anticipated merger with Kimberly-Clark expected to further enhance market competitiveness.
See More
Tech Stock Weighting High, J&J as a Stable Alternative
- Tech Stock Weight Analysis: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating Wall Street's heavy reliance on tech and suggesting that investors may need to diversify to mitigate risk.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, maintains competitiveness through its R&D-driven operations in pharmaceuticals and medical devices, demonstrating a long-term commitment to innovation.
- Dividend King Status: With over 50 consecutive years of dividend increases, Johnson & Johnson showcases its strong and consistent execution, making it a reliable choice for investors, especially during economic fluctuations.
- Resilience of Healthcare Sector: Compared to tech stocks, the healthcare sector exhibits greater stability, as individuals prioritize spending on life-saving medical care even during economic downturns, positioning Johnson & Johnson as an ideal alternative when tech stocks face pressure.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Johnson & Johnson CEO Reaffirms No Plans for GLP-1 Market
- Clear Market Positioning: CEO Joaquin Duato stated that Johnson & Johnson will not enter the rapidly growing GLP-1 obesity drug market, instead focusing on treatments for diseases like cancer, reflecting a strategic decision in oncology.
- Growth Target Set: Duato emphasized that J&J aims to become the world's leading cancer drug maker by 2030, indicating the company's commitment to cancer treatment as a key growth pillar.
- Ongoing R&D Investment: Despite previous failures in Alzheimer's research, J&J continues to invest in R&D for neurodegenerative diseases, showcasing its concern and responsibility towards significant public health issues.
- Business Restructuring Progress: Following the spin-off of its consumer healthcare business in 2023, J&J is in the early phase of its growth cycle, with plans to separate its orthopedics unit, indicating potential in its pharma and MedTech divisions.
See More
Investment Alternatives Amid Tech Stock Surge
- Market Volatility Risk: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating a heavy reliance on tech, prompting investors to consider diversification to mitigate risks.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, demonstrates sustained innovation through its research-driven operations in pharmaceuticals and medical devices, ensuring it remains competitive in a fierce market.
- Stable Dividend Returns: With over 50 consecutive years of dividend increases, Johnson & Johnson has earned the title of 'Dividend King', reflecting its strong execution and business resilience, appealing to investors seeking stable returns.
- Healthcare Sector Resilience: Demand for medical services remains steady during economic downturns, and Johnson & Johnson's business exhibits higher stability amid economic fluctuations, making it a solid alternative to tech stocks.
See More
2026 Consumer Goods Market Analysis
- Church & Dwight's Strong Performance: Church & Dwight (CHD) achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, indicating the company's ability to navigate inflation through volume growth rather than price increases, thereby enhancing its market competitiveness.
- Keurig Dr Pepper's Growth Potential: Despite a nearly 29% decline from its 2025 peak, Keurig Dr Pepper (KDP) expects its energy drink portfolio to generate over $1 billion in annual retail sales, showcasing strong market demand and growth potential.
- Kenvue's Merger Prospects: Kenvue (KVUE) reported an 8.4% growth in its skin health and beauty division in Q1 2026, with quarterly sales reaching $1 billion, and the anticipated merger with Kimberly-Clark (KMB) is expected to further strengthen its market position and pricing power.
- Robust Investment Amid Market Uncertainty: In an uncertain market, these three companies provide a stable business foundation, making them suitable for investors looking to allocate $1,000 during turbulent times for long-term growth.
See More
Church & Dwight's Growth Strategy Amid Inflation
- Stable Sales Growth: Church & Dwight achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, demonstrating its growth strategy focused on volume rather than price increases, which enhances its competitive edge in an inflationary environment.
- Acquisition to Expand Market Share: The company acquired the fast-growing stain-removal brand Miss Mouth's Messy Eater for $325 million, continuing its decade-long acquisition strategy aimed at expanding market share without increasing leverage, thereby solidifying its position in the consumer goods market.
- Energy Drink Portfolio Growth: Keurig Dr Pepper's energy drink portfolio is expected to exceed $1 billion in annual retail sales, and despite a 29% decline in stock price, its low double-digit adjusted earnings growth forecast indicates potential in the youth market, boosting investor confidence.
- Strong Performance in Beauty Health Segment: Kenvue's skin health and beauty division grew 8.4% in Q1 2026, reaching $1 billion in quarterly sales, reflecting stable consumer demand amid economic uncertainty, with the anticipated merger with Kimberly-Clark expected to further enhance market competitiveness.
See More
Tech Stock Weighting High, J&J as a Stable Alternative
- Tech Stock Weight Analysis: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating Wall Street's heavy reliance on tech and suggesting that investors may need to diversify to mitigate risk.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, maintains competitiveness through its R&D-driven operations in pharmaceuticals and medical devices, demonstrating a long-term commitment to innovation.
- Dividend King Status: With over 50 consecutive years of dividend increases, Johnson & Johnson showcases its strong and consistent execution, making it a reliable choice for investors, especially during economic fluctuations.
- Resilience of Healthcare Sector: Compared to tech stocks, the healthcare sector exhibits greater stability, as individuals prioritize spending on life-saving medical care even during economic downturns, positioning Johnson & Johnson as an ideal alternative when tech stocks face pressure.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Johnson & Johnson CEO Reaffirms No Plans for GLP-1 Market
- Clear Market Positioning: CEO Joaquin Duato stated that Johnson & Johnson will not enter the rapidly growing GLP-1 obesity drug market, instead focusing on treatments for diseases like cancer, reflecting a strategic decision in oncology.
- Growth Target Set: Duato emphasized that J&J aims to become the world's leading cancer drug maker by 2030, indicating the company's commitment to cancer treatment as a key growth pillar.
- Ongoing R&D Investment: Despite previous failures in Alzheimer's research, J&J continues to invest in R&D for neurodegenerative diseases, showcasing its concern and responsibility towards significant public health issues.
- Business Restructuring Progress: Following the spin-off of its consumer healthcare business in 2023, J&J is in the early phase of its growth cycle, with plans to separate its orthopedics unit, indicating potential in its pharma and MedTech divisions.
See More
